Activation of Ras/MAPK and mTOR pathways in hepatocellular carcinoma: Tumor growth inhibition with Ras/mTOR pathway abrogation by a novel combination of Sorafenib and rapamycin
Philippa Newell, Josep M. Llovet(Icahn School of Medicine at Mount Sinai), Judit Peix, Augusto Villanueva(NYU Langone Health), Scott L. Friedman(Icahn School of Medicine at Mount Sinai), Isabel Fiel(Icahn School of Medicine at Mount Sinai), Swan N. Thung(Icahn School of Medicine at Mount Sinai), Steven Yea(Array BioPharma (United States)), Sasan Roayaie(White Plains Hospital), Myron Schwartz(Icahn School of Medicine at Mount Sinai)
Cited by 0
Related Papers
Hepatocellular carcinoma
|Nature Reviews Disease Primers|2021|6.6k
Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
|Journal of Hepatology|2001|4.1k
Hepatocellular carcinoma
|Nature Reviews Disease Primers|2016|2.7k
Molecular Regulation of Hepatic Fibrosis, an Integrated Cellular Response to Tissue Injury
|Journal of Biological Chemistry|2000|2.1k